Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Phase III-Expert Panel Review
1.3.4. Assumptions
Chapter 2. Executive Summary
2.1. Global Opioid Induced Constipation Drugs Market Portraiture
2.2. Global Opioid Induced Constipation Drugs Market, by Drug Type, 2017 (US$ Mn)
2.3. Global Opioid Induced Constipation Drugs Market, by Prescription Type, 2017 (US$ Mn)
2.4. Global Opioid Induced Constipation Drugs Market, by Geography, 2017 (US$ Mn)
Chapter 3. Opioid Induced Constipation Drugs Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Top 3 Countries: Global Opioid Induced Constipation Drugs Market, 2016-2026 (US$ Mn)
3.7. Competitive Landscape: Global Opioid Induced Constipation Drugs Market, by Key Players, 2016-2026 (US$ Mn)
Chapter 4. Global Opioid Induced Constipation Drugs Market, by Drug Type, 2016 – 2026 (US$ Mn)
4.1. Overview
4.1.1. Competitive Analysis: Global Opioid Induced Constipation Drugs Market, by Drug Type, 2017 Vs. 2026 (Value %)
4.2. Methylnaltrexone Bromide
4.3. Lubiprostone
4.4. Naloxegol
4.5. Naldemedine
4.6. Docusate Sodium
4.7. Others
4.8. Pipeline Analysis
4.8.1. Phase III Drugs (Estimation till 2026 (US$ Mn))
4.8.1.1. Elobixibat
4.8.2. Phase II Drugs (Qualitative Information)
4.8.2.1. Dolcanatide
Chapter 5. Global Opioid Induced Constipation Drugs Market, by Prescription Type, 2016 – 2026 (US$ Mn)
5.1. Overview
5.1.1. Competitive Analysis: Global Opioid Induced Constipation Drugs Market, by Prescription Type, 2017 Vs. 2026 (Value %)
5.2. Prescribed
5.2.1. Branded
5.2.2. Generic
5.3. Over the Counter (OTC)
Chapter 6. Global Opioid Induced Constipation Drugs Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. Overview
6.2. North America Opioid Induced Constipation Drugs Market Analysis, 2016 – 2026 (US$ Mn)
6.2.1. North America Opioid Induced Constipation Drugs Market, by Country, 2016 – 2026 (US$ Mn)
6.2.1.1. U.S.
6.2.1.2. Canada
6.3. Europe Opioid Induced Constipation Drugs Market Analysis, 2016 – 2026 (US$ Mn)
6.3.1. Europe Opioid Induced Constipation Drugs Market, by Country, 2016 – 2026 (US$ Mn)
6.3.1.1. U.K.
6.3.1.2. Germany
6.3.1.3. Rest of Europe
6.4. Asia Pacific Opioid Induced Constipation Drugs Market Analysis, 2016 – 2026 (US$ Mn)
6.4.1. Asia Pacific Opioid Induced Constipation Drugs Market, by Country, 2016 – 2026 (US$ Mn)
6.4.1.1. China
6.4.1.2. Japan
6.4.1.3. Rest of APAC
6.5. Latin America Opioid Induced Constipation Drugs Market Analysis, 2016 – 2026 (US$ Mn)
6.5.1. Latin America Opioid Induced Constipation Drugs Market, by Country, 2016 – 2026 (US$ Mn)
6.5.1.1. Brazil
6.5.1.2. Mexico
6.5.1.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Opioid Induced Constipation Drugs Market Analysis, 2016 – 2026 (US$ Mn)
6.6.1. MEA Opioid Induced Constipation Drugs Market, by Region, 2016 – 2026 (US$ Mn)
6.6.1.1. GCC
6.6.1.2. Rest of MEA
Chapter 7. Company Profiles
7.1. AstraZeneca plc
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Cubist Pharmaceuticals (Adolor Corporation)
7.3. Daiichi Sankyo Co., Ltd.
7.4. Ironwood Pharmaceuticals, Inc.
7.5. Pfizer, Inc.
7.6. Progenics Pharmaceuticals, Inc.
7.7. Salix Pharmaceuticals Ltd.
7.8. Shionogo & Co., Ltd.
7.9. Sucampo Pharmaceuticals, Inc.
7.10. Synergy Pharmaceuticals, Inc.
List Of Figures
FIG. 1 Opioid Induced Constipation Drugs: Market Segmentation
FIG. 2 Global Opioid Induced Constipation Drugs Market Share, by Drug Type, 2017 (US$ Mn)
FIG. 3 Global Opioid Induced Constipation Drugs Market, by Prescription Type, 2017 (US$ Mn)
FIG. 4 Global Opioid Induced Constipation Drugs Market Share, by Geography, 2017 (US$ Mn)
FIG. 5 Attractive Investment Proposition, by Geography, 2017
FIG. 6 Top 3 Countries: Global Opioid Induced Constipation Drugs Market, 2016-2026 (US$ Mn)
FIG. 7 Market Competition Landscape, by Key Players, 2017
FIG. 8 Competitive Analysis: Global Opioid Induced Constipation Drugs Market, by Drug Type, 2017 Vs. 2026 (Value %)
FIG. 9 Global Methylnaltrexone Bromide Drug Market for Opioid Induced Constipation, 2016 – 2026 (US$ Mn)
FIG. 10 Global Lubiprostone Drug Market for Opioid Induced Constipation, 2016 – 2026 (US$ Mn)
FIG. 11 Global Naloxegol Drug Market for Opioid Induced Constipation, 2016 – 2026 (US$ Mn)
FIG. 12 Global Naldemedine Drug Market for Opioid Induced Constipation, 2016 – 2026 (US$ Mn)
FIG. 13 Global Docusate Sodium Drug Market for Opioid Induced Constipation, 2016 – 2026 (US$ Mn)
FIG. 14 Global Other Drugs Market for Opioid Induced Constipation, 2016 – 2026 (US$ Mn)
FIG. 15 Competitive Analysis: Global Opioid Induced Constipation Drugs Market, by Prescription Type, 2017 Vs. 2026 (Value %)
FIG. 16 Global Branded Drugs Market for Opioid Induced Constipation, 2016 – 2026 (US$ Mn)
FIG. 17 Global Generic Drugs Market for Opioid Induced Constipation, 2016 – 2026 (US$ Mn)
FIG. 18 Global Over the Counter Drugs Market for Opioid Induced Constipation, 2016 – 2026 (US$ Mn)
FIG. 19 U.S. Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 20 Canada Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 21 U.K. Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 22 Germany Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 23 Rest of Europe Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 24 China Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 25 Japan Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 26 Rest of Asia Pacific Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 27 Brazil Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 28 Mexico Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 29 Rest of Latin America Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 30 GCC Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 31 Rest of Middle East and Africa Opioid Induced Constipation Drugs Market, 2016 – 2026 (US$ Mn)
List Of Table
TABLE 1 Global Opioid Induced Constipation Drugs Market Portraiture
TABLE 2 Global Opioid Induced Constipation Drugs Market, by Drug Type, 2016 – 2026 (US$ Mn)
TABLE 3 Global Opioid Induced Constipation Drugs Market, by Prescription Type, 2016 – 2026 (US$ Mn)
TABLE 4 Global Prescribed Drugs Market for Opioid Induced Constipation, by Prescription Type, 2016 – 2026 (US$ Mn)
TABLE 5 Global Opioid Induced Constipation Drugs Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 6 North America Opioid Induced Constipation Drugs Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 7 Europe Opioid Induced Constipation Drugs Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 8 Asia Pacific Opioid Induced Constipation Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 9 Latin America Opioid Induced Constipation Drugs Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 10 Middle East and Africa Opioid Induced Constipation Drugs Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 11 AstraZeneca plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 12 Cubist Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 13 Daiichi Sankyo Co., Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 14 Ironwood Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 15 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16 Progenics Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17 Salix Pharmaceuticals Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18 Shionogo & Co., Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 Sucampo Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 Synergy Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)